Cargando…
Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial
BACKGROUND: Colorectal cancer (CRC) is the second most common cause of all cancer deaths in Europe and the Western world with a lifetime risk of approximately 5%. Despite several improvements in the treatment of patients with unresectable CRC prognosis is poor and there is the need of developing new...
Autores principales: | Burock, Susen, Daum, Severin, Keilholz, Ulrich, Neumann, Konrad, Walther, Wolfgang, Stein, Ulrike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856000/ https://www.ncbi.nlm.nih.gov/pubmed/29544454 http://dx.doi.org/10.1186/s12885-018-4197-9 |
Ejemplares similares
-
Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis
por: Kortüm, Benedikt, et al.
Publicado: (2022) -
SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer
por: Schmid, Felicitas, et al.
Publicado: (2012) -
Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker
por: Schmid, Felicitas, et al.
Publicado: (2022) -
The different clonal origins of metachronous and synchronous metastases
por: Gofrit, Ofer N., et al.
Publicado: (2023) -
Circulating MACC1 Transcripts in Colorectal Cancer Patient Plasma Predict Metastasis and Prognosis
por: Stein, Ulrike, et al.
Publicado: (2012)